PANTHERx® Rare Selected by Ionis Pharmaceuticals
PANTHERx® Rare, renowned for its pivotal role in providing patient access and support services for rare diseases, has been honored with the selection by Ionis Pharmaceuticals, Inc. This strategic partnership aims to facilitate the distribution of TRYNGOLZA™ (olezarsen), a groundbreaking treatment recognized by the U.S. Food and Drug Administration (FDA) for reducing triglyceride levels in adults suffering from familial chylomicronemia syndrome (FCS).
Understanding TRYNGOLZA™ (olezarsen)
TRYNGOLZA™ is identified as a GalNAc3-conjugated antisense oligonucleotide therapy, designed to selectively target and degrade apoC-III mRNA. This process plays a crucial role in curbing the hepatic production of apoC-III, a protein integral to triglyceride metabolism. FCS, a rare genetic disorder, is marked by extremely elevated plasma triglyceride levels, largely stemming from mutations in the LPL gene. These mutations significantly hinder the functionality of the lipoprotein lipase (LPL) enzyme, which is essential for metabolizing chylomicrons—large particles primarily composed of triglycerides.
The Implications of Familial Chylomicronemia Syndrome (FCS)
In patients with FCS, the impaired ability to break down chylomicrons can lead to a hazardous accumulation of triglycerides in the bloodstream. Such a build-up drastically elevates the risk of acute pancreatitis, a condition that not only entails severe discomfort but can also cause lasting pancreatic damage and, in severe cases, can be life-threatening if not adequately managed. Furthermore, the physical and emotional toll of these symptoms, including hepatosplenomegaly (enlargement of the liver and spleen), chronic fatigue, debilitating abdominal pain, and cognitive impacts such as memory impairment, significantly affects patients' quality of life.
The Partnership's Vision
Rob Snyder, the Executive Chair of PANTHERx® Rare Pharmacy, emphasized the importance of this collaboration with Ionis. He stated, "This partnership will help to redefine life for adults with FCS by streamlining the access and support process. We are excited about the prospect of meeting the needs of patients grappling with this challenging condition by making the pathway to receive their medication more efficient and approachable."
A Commitment to Rare Diseases
PANTHERx Rare, distinguished by dual accreditation, focuses its efforts on supporting individuals grappling with rare and orphan diseases. This specialty pharmacy not only distributes various orphan products but also emphasizes critical access and support services for affected patients. By delivering medicinal breakthroughs along with clinical excellence, PANTHERx strives to transform the lives of those facing devastating health challenges.
The Landscape of Rare Diseases
Currently, the landscape of rare diseases shows a staggering impact, affecting an estimated 25 to 30 million Americans. With over 7,000 rare diseases identified, a significant challenge remains—over 90% lack FDA-approved treatments. However, an increase in federal support and scientific advancements has ushered in a wave of FDA orphan drug approvals, offering a renewed hope to the rare disease community.
Acknowledgments of Excellence
PANTHERx holds twin accreditations, including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and the URAC Rare Disease Center of Excellence. Their focus on enhancing patient satisfaction has earned them the prestigious MMIT Patient Choice Award six times, a testament to their dedication and service. PANTHERx is headquartered in Pittsburgh, Pennsylvania, and operates across all 50 states and U.S. territories, aiming to serve patients more effectively.
Frequently Asked Questions
What is TRYNGOLZA™?
TRYNGOLZA™ (olezarsen) is a treatment approved to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
Who is distributing TRYNGOLZA™?
PANTHERx® Rare has been selected by Ionis Pharmaceuticals for the distribution of TRYNGOLZA™.
What is familial chylomicronemia syndrome?
FCS is a rare genetic disorder characterized by extreme elevations of triglycerides in the blood, often due to mutations affecting the lipoprotein lipase enzyme.
What symptoms are associated with FCS?
Symptoms can include abdominal pain, chronic fatigue, and liver and spleen enlargement, along with potential cognitive impacts.
How does PANTHERx support rare disease patients?
PANTHERx provides access to orphan therapies and offers patient support services, transforming lives with essential healthcare solutions.
